FIELD: biotechnology.
SUBSTANCE: present invention refers to biotechnology. In particular, the invention refers to therapy of human malignant tumours. More specifically, the present invention refers to oncolytic adenoviral vectors separately or together with therapeutic compositions for therapeutic use and to methods of treating malignant tumours. In one aspect, the present invention refers to the separate administration of an adaptive cell therapeutic composition and oncolytic adenoviral vectors. Present invention also relates to a pharmaceutical kit and a pharmaceutical composition which use oncolytic adenoviral vectors.
EFFECT: invention is intended for therapeutic application and to methods of treating malignant tumours.
5 cl, 51 dwg, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ONCOLYTIC ADENOVIRUSES ENCODING BISPECIFIC ANTIBODIES, AS WELL AS METHODS AND APPLICATIONS ASSOCIATED THEREWITH | 2016 |
|
RU2725799C2 |
| NEW MEDICAL AGENTS AND USE THEREOF | 2015 |
|
RU2739073C2 |
| ADENOVIRAL VECTORS AND RELATED METHODS AND APPLICATIONS | 2009 |
|
RU2520823C2 |
| MODIFIED ONCOLYTIC ADENO VIRUSES | 2019 |
|
RU2788638C2 |
| THERAPEUTIC COMPOSITIONS AND METHODS OF USING FOR TREATING CANCER | 2016 |
|
RU2720984C2 |
| CHIMERIC ADENOVIRUSES APPLICABLE FOR TREATING MALIGNANT GROWTH | 2005 |
|
RU2448157C2 |
| COATED ONCOLYTIC ADENOVIRUS FOR ANTICANCER VACCINES | 2015 |
|
RU2695375C2 |
| ONCOLYTIC ADENOVIRUS FOR TREATING CANCER, USING IT, AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2010 |
|
RU2536931C2 |
| ADENOVIRUS/ALFAVIRUS HYBRID VECTOR FOR EFFECTIVE ADMINISTRATION AND EXPRESSION OF THERAPEUTIC GENES IN TUMOR CELLS | 2005 |
|
RU2394104C2 |
| GENETIC VECTOR Ad6/3-hTERT-GMCSF CONTAINING GENOMIC SEQUENCES OF RECOMBINANT ADENOVIRUS SEROTYPE 6, HUMAN TELOMERASE PROMOTER, HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GENE, AS WELL AS FIBER PROTEIN GENE WITH INSERTION OF FIBER KNOB DOMAIN OF ADENOVIRUS SEROTYPE 3 WITH INCREASED TRANSDUCTION INTO TUMOR CELLS | 2023 |
|
RU2814581C1 |
